US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
US6562594B1
(en)
|
1999-09-29 |
2003-05-13 |
Diversa Corporation |
Saturation mutagenesis in directed evolution
|
US6358709B1
(en)
|
1995-12-07 |
2002-03-19 |
Diversa Corporation |
End selection in directed evolution
|
US6939689B2
(en)
|
1995-12-07 |
2005-09-06 |
Diversa Corporation |
Exonuclease-mediated nucleic acid reassembly in directed evolution
|
US6361974B1
(en)
|
1995-12-07 |
2002-03-26 |
Diversa Corporation |
Exonuclease-mediated nucleic acid reassembly in directed evolution
|
US6238884B1
(en)
|
1995-12-07 |
2001-05-29 |
Diversa Corporation |
End selection in directed evolution
|
US6537776B1
(en)
|
1999-06-14 |
2003-03-25 |
Diversa Corporation |
Synthetic ligation reassembly in directed evolution
|
US6352842B1
(en)
|
1995-12-07 |
2002-03-05 |
Diversa Corporation |
Exonucease-mediated gene assembly in directed evolution
|
US7018793B1
(en)
|
1995-12-07 |
2006-03-28 |
Diversa Corporation |
Combinatorial screening of mixed populations of organisms
|
US6171820B1
(en)
|
1995-12-07 |
2001-01-09 |
Diversa Corporation |
Saturation mutagenesis in directed evolution
|
US6740506B2
(en)
|
1995-12-07 |
2004-05-25 |
Diversa Corporation |
End selection in directed evolution
|
US5830696A
(en)
|
1996-12-05 |
1998-11-03 |
Diversa Corporation |
Directed evolution of thermophilic enzymes
|
US6713279B1
(en)
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
US7122636B1
(en)
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
US7112655B1
(en)
|
1997-02-27 |
2006-09-26 |
Japan Tobacco, Inc. |
JTT-1 protein and methods of inhibiting lymphocyte activation
|
JP3521382B2
(ja)
|
1997-02-27 |
2004-04-19 |
日本たばこ産業株式会社 |
細胞間接着及びシグナル伝達を媒介する細胞表面分子
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US7365166B2
(en)
|
1997-04-07 |
2008-04-29 |
Genentech, Inc. |
Anti-VEGF antibodies
|
DE69829891T2
(de)
*
|
1997-04-07 |
2005-10-06 |
Genentech, Inc., South San Francisco |
Anti-VEGF Antikörper
|
US20020032315A1
(en)
*
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
US6864227B1
(en)
|
1998-04-13 |
2005-03-08 |
California Institute Of Technology |
Artery-and vein-specific proteins and uses therefor
|
US6887674B1
(en)
|
1998-04-13 |
2005-05-03 |
California Institute Of Technology |
Artery- and vein-specific proteins and uses therefor
|
ES2301254T3
(es)
|
1998-11-18 |
2008-06-16 |
Genentech, Inc. |
Variantes de anticuerpos con una afinidad de union mayor en comparacion con los anticuerpos parentales.
|
SI1135498T1
(sl)
|
1998-11-18 |
2008-06-30 |
Genentech Inc |
Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
|
WO2000034337A1
(en)
*
|
1998-12-10 |
2000-06-15 |
Tsukuba Research Laboratory, Toagosei Co., Ltd. |
Humanized monoclonal antibodies against vascular endothelial cell growth factor
|
IL143596A0
(en)
|
1998-12-22 |
2002-04-21 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists and uses thereof
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
NZ514918A
(en)
*
|
1999-04-28 |
2003-11-28 |
Univ Texas |
Compositions and methods for cancer treatment by selectively inhibiting VEGF
|
EP1203026A4
(en)
*
|
1999-07-29 |
2005-03-16 |
Dyax Corp |
FRACTIONS BINDING FIBRIN
|
JP3871503B2
(ja)
|
1999-08-30 |
2007-01-24 |
日本たばこ産業株式会社 |
免疫性疾患治療剤
|
JP4210454B2
(ja)
|
2001-03-27 |
2009-01-21 |
日本たばこ産業株式会社 |
炎症性腸疾患治療剤
|
EP1757311B1
(en)
|
1999-12-24 |
2009-02-11 |
Genentech, Inc. |
Methods and compositions for prolonging elimination half-times of bioactive compounds
|
PT1240337E
(pt)
|
1999-12-24 |
2007-01-31 |
Genentech Inc |
Métodos e composições para prolongar as meias-vidas de eliminação de compostos bioactivos
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
JP3597140B2
(ja)
|
2000-05-18 |
2004-12-02 |
日本たばこ産業株式会社 |
副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
|
EP2077276A1
(en)
|
2000-06-23 |
2009-07-08 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogensis
|
EP2275549A1
(en)
|
2000-06-23 |
2011-01-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
US6902718B2
(en)
|
2000-10-24 |
2005-06-07 |
Diatide, Inc. |
Stabilization of radiopharmaceutical compositions using hydrophilic thioethers
|
US6989138B2
(en)
|
2000-10-24 |
2006-01-24 |
Diatide, Inc. |
Stabilization of radiopharmaceutical compositions using hydrophilic thioethers and hydrophilic 6-hydroxy chromans
|
JP4212278B2
(ja)
|
2001-03-01 |
2009-01-21 |
日本たばこ産業株式会社 |
移植片拒絶反応抑制剤
|
US7117096B2
(en)
|
2001-04-17 |
2006-10-03 |
Abmaxis, Inc. |
Structure-based selection and affinity maturation of antibody library
|
US7667004B2
(en)
|
2001-04-17 |
2010-02-23 |
Abmaxis, Inc. |
Humanized antibodies against vascular endothelial growth factor
|
TWI284539B
(en)
|
2001-07-30 |
2007-08-01 |
Epix Pharm Inc |
A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US20030157108A1
(en)
*
|
2001-10-25 |
2003-08-21 |
Genentech, Inc. |
Glycoprotein compositions
|
US20030190705A1
(en)
*
|
2001-10-29 |
2003-10-09 |
Sunol Molecular Corporation |
Method of humanizing immune system molecules
|
WO2003066662A2
(en)
|
2002-02-05 |
2003-08-14 |
Genentech, Inc. |
Protein purification
|
EP1501369B1
(en)
|
2002-04-26 |
2015-06-24 |
Genentech, Inc. |
Non-affinity purification of proteins
|
KR101086533B1
(ko)
|
2002-05-24 |
2011-11-23 |
쉐링 코포레이션 |
중화 사람 항-igfr 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
US9028822B2
(en)
|
2002-06-28 |
2015-05-12 |
Domantis Limited |
Antagonists against TNFR1 and methods of use therefor
|
BR0312692A
(pt)
|
2002-07-15 |
2007-06-26 |
Univ Texas |
anticorpos selecionados e peptìdeos de duramicina que se ligam a fosfolipìdios aniÈnicos e aminofosfolipìdios e seus usos no tratamento de infecções virais e cáncer
|
CA2965865C
(en)
|
2002-07-18 |
2021-10-19 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
CA2513113A1
(en)
*
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
WO2004070016A2
(en)
|
2003-02-03 |
2004-08-19 |
Fraunhofer Usa Inc. |
System for expression of genes in plants
|
WO2004080418A2
(en)
|
2003-03-12 |
2004-09-23 |
Vasgene Therapeutics, Inc. |
Nucleic acid compounds for inhibiting angiogenesis and tumor growth
|
US7381410B2
(en)
|
2003-03-12 |
2008-06-03 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
US8431396B2
(en)
|
2003-03-21 |
2013-04-30 |
The Cleveland Clinic Foundation |
Anti-angiogenic peptides
|
WO2005026375A2
(en)
|
2003-05-22 |
2005-03-24 |
Fraunhofer Usa, Inc. |
Recombinant carrier molecule for expression, delivery and purification of target polypeptides
|
KR20160114727A
(ko)
|
2003-05-30 |
2016-10-05 |
제넨테크, 인크. |
항-vegf 항체를 사용한 치료
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
CA2527694C
(en)
*
|
2003-05-30 |
2015-07-14 |
Hendricus Renerus Jacobus Mattheus Hoogenboom |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
ES2786568T3
(es)
|
2003-07-28 |
2020-10-13 |
Genentech Inc |
Reducción de la lixiviación de la proteína A durante la cromatografía de afinidad con proteína A
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
WO2005012531A2
(en)
*
|
2003-08-01 |
2005-02-10 |
Genentech, Inc. |
Antibody cdr polypeptide sequences with restricted diversity
|
US7758859B2
(en)
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US7920906B2
(en)
|
2005-03-10 |
2011-04-05 |
Dexcom, Inc. |
System and methods for processing analyte sensor data for sensor calibration
|
ES2388138T3
(es)
|
2003-08-27 |
2012-10-09 |
Ophthotech Corporation |
Terapia de combinación para tratamiento de trastornos neovasculares oculares
|
FR2859725B1
(fr)
*
|
2003-09-16 |
2006-03-10 |
Neovacs |
Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
|
US9247900B2
(en)
|
2004-07-13 |
2016-02-02 |
Dexcom, Inc. |
Analyte sensor
|
JP5912211B2
(ja)
|
2004-01-20 |
2016-04-27 |
メルス ビー.ヴィー. |
結合タンパク質の混合物
|
ES2337473T3
(es)
|
2004-02-19 |
2010-04-26 |
Genentech, Inc. |
Anticuerpos reparadores con cdr.
|
AU2005224081B2
(en)
|
2004-03-12 |
2011-06-30 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
DE602005025459D1
(de)
|
2004-03-12 |
2011-02-03 |
Vasgene Therapeutics Inc |
Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
|
KR20120133403A
(ko)
|
2004-06-01 |
2012-12-10 |
도만티스 리미티드 |
증강된 혈청 반감기를 가지는 이특이성 융합 항체
|
US8989833B2
(en)
|
2004-07-13 |
2015-03-24 |
Dexcom, Inc. |
Transcutaneous analyte sensor
|
WO2006127694A2
(en)
|
2004-07-13 |
2006-11-30 |
Dexcom, Inc. |
Analyte sensor
|
BRPI0513534A
(pt)
|
2004-07-20 |
2008-05-06 |
Genentech Inc |
inibidores de proteìna 4 semelhante à angiopoietina, combinações, e seu uso
|
US8604185B2
(en)
|
2004-07-20 |
2013-12-10 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
CN101048427B
(zh)
|
2004-07-23 |
2015-01-14 |
健泰科生物技术公司 |
抗体或其片段的结晶
|
US7655229B2
(en)
|
2004-09-02 |
2010-02-02 |
Chan Andrew C |
Anti-FC-gamma RIIB receptor antibody and uses therefor
|
US7662926B2
(en)
|
2004-09-02 |
2010-02-16 |
Genentech, Inc. |
Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
|
ES2529451T3
(es)
|
2004-09-23 |
2015-02-20 |
Vasgene Therapeutics, Inc. |
Compuestos polipeptídicos para inhibir la angiogénesis y el crecimiento tumoral
|
WO2006047325A1
(en)
|
2004-10-21 |
2006-05-04 |
Genentech, Inc. |
Method for treating intraocular neovascular diseases
|
ZA200704934B
(en)
|
2004-12-22 |
2010-09-29 |
Genentech Inc |
Methods for producing soluble multi-membrane-spanning proteins
|
JP5057994B2
(ja)
*
|
2005-01-06 |
2012-10-24 |
ジーイー・ヘルスケア・アクスイェ・セルスカプ |
光学イメージング
|
RU2452482C2
(ru)
|
2005-02-18 |
2012-06-10 |
АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи |
Комбинация и способы введения терапевтических средств и комбинированной терапии
|
US20070166388A1
(en)
|
2005-02-18 |
2007-07-19 |
Desai Neil P |
Combinations and modes of administration of therapeutic agents and combination therapy
|
US8735394B2
(en)
|
2005-02-18 |
2014-05-27 |
Abraxis Bioscience, Llc |
Combinations and modes of administration of therapeutic agents and combination therapy
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
EP2586459B1
(en)
|
2005-03-25 |
2017-05-24 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonist formulations
|
EP1879587A2
(en)
*
|
2005-04-15 |
2008-01-23 |
Schering Corporation |
Methods and compositions for treating or preventing cancer
|
AU2006261357A1
(en)
*
|
2005-06-17 |
2006-12-28 |
Zimmer Spine Austin, Inc. |
Improved method of treating degenerative spinal disorders
|
BRPI0622254A2
(pt)
*
|
2005-06-20 |
2011-08-09 |
Genentech Inc |
anticorpo isolado, conjugado de droga e anticorpo, formulação farmacêutica, método de inibição da proliferação celular, método de tratamento de cáncer, teste de detecção de células cancerosas, artigo industrializado, uso de um composto conjugado de droga e anticorpo e uso de uma formulação farmacêutica
|
USRE47223E1
(en)
|
2005-06-20 |
2019-02-05 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US8962278B2
(en)
|
2005-08-03 |
2015-02-24 |
Ibio Inc. |
Compositions and methods for production of immunoglobulins
|
TWI429452B
(zh)
|
2005-08-31 |
2014-03-11 |
Abraxis Bioscience Llc |
包含弱水溶性藥劑及抗微生物劑之組合物
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
KR100877824B1
(ko)
|
2005-11-11 |
2009-01-12 |
한국생명공학연구원 |
E2epf ucp-vhl 상호작용 및 그 용도
|
EP1959958A4
(en)
*
|
2005-11-14 |
2010-07-14 |
Univ Southern California |
INTEGRIN-BINDING SMALL MOLECULES
|
AU2006323412A1
(en)
*
|
2005-12-06 |
2007-06-14 |
Domantis Limited |
Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
|
WO2007070671A2
(en)
†
|
2005-12-16 |
2007-06-21 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic methods for inhibiting tumor growth with dll4 antagonists
|
US8101365B2
(en)
|
2006-01-05 |
2012-01-24 |
Genentech, Inc. |
Anti-EphB4 antibodies and methods using same
|
KR101617108B1
(ko)
|
2006-01-20 |
2016-04-29 |
제넨테크, 인크. |
항-ephrinb2 항체 및 그의 사용 방법
|
KR20080106433A
(ko)
|
2006-02-13 |
2008-12-05 |
프라운호퍼 유에스에이, 인코포레이티드 |
인플루엔자 항원, 백신 조성물 및 관련 방법
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
RS54156B1
(en)
|
2006-03-21 |
2015-12-31 |
Genentech Inc. |
COMBINED THERAPY INCLUDING ALFA5BETA1 ANTAGONISTS
|
CN101405030B
(zh)
*
|
2006-03-22 |
2013-03-13 |
霍夫曼-拉罗奇有限公司 |
针对血管内皮生长因子的抗体和针对人表皮生长因子2型受体的抗体在制备治疗肿瘤的试剂盒中的应用
|
TW200812615A
(en)
*
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
JP2009531463A
(ja)
*
|
2006-03-29 |
2009-09-03 |
ジェネンテック・インコーポレーテッド |
腫瘍の診断と治療
|
BRPI0710645A2
(pt)
|
2006-04-07 |
2012-03-20 |
The Procter & Gamble Company |
Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos
|
BRPI0710411A2
(pt)
*
|
2006-06-06 |
2012-04-10 |
Genentch Inc Empresa Americana |
Métodos para tratar um tumor, para tratar uma condição patológica associada à angiogênese, para estimular a proliferação celular endotelial, para reduzir ou inibir a diferenciação celular endotelial, para reduzir ou inibir o desenvolvimento arterial, para reduzir ou inibir a perfusão vascular tumoral para aumentar a eficácia de um agente anti-angiogênico, usos de um antagonista de dll4 e uso de um agonisra de dll4
|
BRPI0710413A2
(pt)
|
2006-06-06 |
2011-08-23 |
Genentech Inc |
anticorpos anti-dll4, isolados, polinucleotìdeo, vetor, célular hospedeira, método para produção de um anticorpo anti-dll4, método para produção de um imunoconjugado anti-dll4, método para a detecção de dll4, metodo para diagnosticar um distúrbio, composições, método para tratar um tumor, cáncer e/ou disturbio da proliferação celular e método para melhorar a eficácia de um agente anti-angiogênico
|
JP5216002B2
(ja)
|
2006-06-16 |
2013-06-19 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
硝子体内投与に適したvegfアンタゴニスト製剤
|
FR2902799B1
(fr)
|
2006-06-27 |
2012-10-26 |
Millipore Corp |
Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
|
EP2068877A4
(en)
|
2006-07-19 |
2011-09-21 |
Cleveland Clinic Foundation |
COMPOUNDS AND METHODS FOR MODULATING ANGIOGENESIS
|
CN100448892C
(zh)
*
|
2006-08-02 |
2009-01-07 |
中国人民解放军军事医学科学院基础医学研究所 |
抗肿瘤血管内皮生长因子受体vegf-r2抗原及其编码基因与应用
|
CN101505792B
(zh)
|
2006-08-21 |
2012-10-03 |
霍夫曼-拉罗奇有限公司 |
使用抗-vegf抗体的肿瘤疗法
|
EA018260B1
(ru)
|
2006-09-29 |
2013-06-28 |
Онкомед Фармасьютикалз, Инк. |
Антитела к дельта-подобному лиганду 4 человека и их применение
|
PL2069798T3
(pl)
|
2006-10-04 |
2014-09-30 |
Genentech Inc |
Test ELISA dla VEGF
|
CN102006885A
(zh)
*
|
2006-10-20 |
2011-04-06 |
先灵公司 |
完全人源抗vegf抗体及其使用方法
|
KR20140031996A
(ko)
*
|
2006-12-19 |
2014-03-13 |
제넨테크, 인크. |
조기 종양의 치료 및 아주반트 및 네오아주반트 요법을 위한 vegf-특이적 길항제
|
US8569464B2
(en)
|
2006-12-21 |
2013-10-29 |
Emd Millipore Corporation |
Purification of proteins
|
US8163886B2
(en)
|
2006-12-21 |
2012-04-24 |
Emd Millipore Corporation |
Purification of proteins
|
US8362217B2
(en)
|
2006-12-21 |
2013-01-29 |
Emd Millipore Corporation |
Purification of proteins
|
KR101431856B1
(ko)
|
2007-01-22 |
2014-08-27 |
제넨테크, 인크. |
항체의 고분자전해질 침전 및 정제
|
EP2125013A4
(en)
*
|
2007-01-26 |
2010-04-07 |
Bioinvent Int Ab |
DLL4 SIGNALING INHIBITOR AND ITS USES
|
AU2008216495A1
(en)
|
2007-02-09 |
2008-08-21 |
Genentech, Inc. |
Anti-Robo4 antibodies and uses therefor
|
CL2008001334A1
(es)
|
2007-05-08 |
2008-09-22 |
Genentech Inc |
Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
|
WO2008143665A1
(en)
|
2007-05-17 |
2008-11-27 |
Genentech, Inc. |
Inhibition of tumor metastasis by anti neuropilin 2 antibodies
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
KR20190140090A
(ko)
|
2007-07-09 |
2019-12-18 |
제넨테크, 인크. |
폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
|
CA2692933C
(en)
|
2007-07-11 |
2016-10-18 |
Fraunhofer Usa, Inc. |
Yersinia pestis antigens, vaccine compositions, and related methods
|
US8975377B2
(en)
|
2007-08-13 |
2015-03-10 |
Vasgene Therapeutics, Inc |
Cancer treatment using humanized antibodies that bind to EphB4
|
EP3492488A1
(en)
|
2007-08-22 |
2019-06-05 |
The Regents of The University of California |
Activatable binding polypeptides and methods of identification and use thereof
|
ES2572958T3
(es)
|
2007-10-30 |
2016-06-03 |
Genentech, Inc. |
Purificación de anticuerpos mediante cromatografía de intercambio catiónico
|
TW200924796A
(en)
*
|
2007-11-09 |
2009-06-16 |
Genentech Inc |
Activin receptor-like kinase-1 compositions and methods of use
|
EP2219672B1
(en)
|
2007-11-09 |
2016-02-17 |
Peregrine Pharmaceuticals, Inc. |
Anti-vegf antibody compositions and methods
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
PL2254571T3
(pl)
|
2008-03-18 |
2015-11-30 |
Genentech Inc |
Kombinacje koniugatu przeciwciała anty-HER2-lek i środki chemioterapeutyczne oraz sposoby zastosowania
|
JP5425180B2
(ja)
*
|
2008-03-27 |
2014-02-26 |
ザイモジェネティクス, インコーポレイテッド |
PDGFRβおよびVEGF−Aを阻害するための組成物および方法
|
EP2280997A2
(en)
*
|
2008-04-18 |
2011-02-09 |
Xencor, Inc. |
Human equivalent monoclonal antibodies engineered from nonhuman variable regions
|
AU2009241589B2
(en)
|
2008-04-29 |
2013-10-10 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
MX2010013236A
(es)
|
2008-06-03 |
2011-02-24 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
EP3002299A1
(en)
|
2008-06-03 |
2016-04-06 |
AbbVie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
WO2009151514A1
(en)
|
2008-06-11 |
2009-12-17 |
Millipore Corporation |
Stirred tank bioreactor
|
HUE032894T2
(hu)
|
2008-06-25 |
2017-11-28 |
Esbatech Alcon Biomed Res Unit |
VEGF-gátló, stabilis és oldható antitestek
|
MX2010014574A
(es)
*
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
|
US20100029491A1
(en)
*
|
2008-07-11 |
2010-02-04 |
Maike Schmidt |
Methods and compositions for diagnostic use for tumor treatment
|
JP5606438B2
(ja)
|
2008-07-23 |
2014-10-15 |
エフ.ホフマン−ラ ロシュ アーゲー |
抗血管新生療法を受容可能な被験体の同定
|
CN102149724B
(zh)
|
2008-08-14 |
2014-04-09 |
健泰科生物技术公司 |
使用原地蛋白质置换离子交换膜层析清除污染物的方法
|
US20100055099A1
(en)
*
|
2008-08-29 |
2010-03-04 |
Ellen Filvaroff |
Diagnostics and Treatments for VEGF-Independent Tumors
|
CA2736029A1
(en)
|
2008-09-05 |
2010-03-11 |
Duke University |
Anti-lipid antibodies
|
KR20110076918A
(ko)
|
2008-09-10 |
2011-07-06 |
제넨테크, 인크. |
단백질의 산화성 분해를 방지하기 위한 조성물 및 방법
|
US8734803B2
(en)
|
2008-09-28 |
2014-05-27 |
Ibio Inc. |
Humanized neuraminidase antibody and methods of use thereof
|
US8268314B2
(en)
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
PE20150682A1
(es)
|
2008-10-14 |
2015-05-20 |
Genentech Inc |
Variantes de inmunoglobulinas y sus usos
|
MX2011004649A
(es)
|
2008-11-03 |
2011-05-30 |
Molecular Partners Ag |
Proteinas de union que inhiben la interaccion en el receptor de vegf-a.
|
ES2498274T3
(es)
|
2008-11-05 |
2014-09-24 |
Genentech, Inc. |
Polimorfismos genéticos en degeneración macular relacionada con la edad
|
MX340724B
(es)
|
2008-11-22 |
2016-07-22 |
Genentech Inc |
Terapia anti-angiogenesis para el tratamiento del cancer de mama.
|
ES2749232T3
(es)
|
2008-12-16 |
2020-03-19 |
Emd Millipore Corp |
Reactor de tanque agitado y procedimiento
|
JP2012512244A
(ja)
|
2008-12-16 |
2012-05-31 |
イー・エム・デイー・ミリポア・コーポレイシヨン |
タンパク質の精製
|
CA2746120A1
(en)
|
2008-12-23 |
2010-07-01 |
Genentech, Inc. |
Methods and compositions for diagnostic use in cancer patients
|
EP3543256A1
(en)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
WO2010081838A2
(en)
|
2009-01-14 |
2010-07-22 |
Novartis Ag |
Sterile prefilled container
|
CN102333544A
(zh)
|
2009-02-06 |
2012-01-25 |
通用医疗公司 |
治疗血管损伤的方法
|
CN102481341B
(zh)
|
2009-02-23 |
2017-05-17 |
希托马克斯医疗有限公司 |
蛋白原及其使用方法
|
CN102333548B
(zh)
|
2009-02-27 |
2013-01-30 |
健泰科生物技术公司 |
用于蛋白质标记的方法和组合物
|
BRPI1008955A2
(pt)
|
2009-03-13 |
2015-09-01 |
Abraxis Bioscience Llc |
Terapia de combinação com derivados de tiocolchicina.
|
WO2010111254A1
(en)
|
2009-03-25 |
2010-09-30 |
Genentech, Inc. |
Novel anti-alpha5beta1 antibodies and uses thereof
|
PE20120591A1
(es)
|
2009-04-02 |
2012-05-23 |
Roche Glycart Ag |
Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
|
PL2417156T3
(pl)
|
2009-04-07 |
2015-07-31 |
Roche Glycart Ag |
Trójwartościowe, bispecyficzne przeciwciała
|
MX2011010908A
(es)
*
|
2009-04-16 |
2012-02-21 |
Abbott Biotherapeutics Corp |
Anticuerpos anti-tnf-alfa y sus usos.
|
SG175289A1
(en)
*
|
2009-04-20 |
2011-11-28 |
Genentech Inc |
Adjuvant cancer therapy
|
US9067986B2
(en)
|
2009-04-27 |
2015-06-30 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
EP2427479B1
(en)
|
2009-05-07 |
2018-11-21 |
The Regents of The University of California |
Antibodies and methods of use thereof
|
CA2665956A1
(en)
*
|
2009-05-07 |
2010-11-07 |
Samir Patel |
Combination treatment for ocular diseases
|
KR101754433B1
(ko)
|
2009-05-08 |
2017-07-05 |
백시넥스 인코포레이티드 |
항-cd100 항체 및 이의 사용 방법
|
AR076662A1
(es)
|
2009-05-08 |
2011-06-29 |
Genentech Inc |
Anticuerpos anti-egfl7 humanizados y metodos de uso de los mismos
|
EP2443234B1
(en)
|
2009-06-15 |
2018-08-15 |
Icon Genetics GmbH |
Nicotiana benthamiana plants deficient in xylosyltransferase activity
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
SG177640A1
(en)
|
2009-07-13 |
2012-02-28 |
Genentech Inc |
Diagnostic methods and compositions for treatment of cancer
|
AR078060A1
(es)
|
2009-07-14 |
2011-10-12 |
Novartis Ag |
Descontaminacion de superficie de contenedores previamente llenados en empaque secundario
|
WO2011014457A1
(en)
|
2009-07-27 |
2011-02-03 |
Genentech, Inc. |
Combination treatments
|
CA2769308A1
(en)
|
2009-07-31 |
2011-02-03 |
Genentech, Inc. |
Inhibition of tumor metastasis using bv8- or g-csf-antagonists
|
KR20200111282A
(ko)
|
2009-08-11 |
2020-09-28 |
제넨테크, 인크. |
글루타민-비함유 세포 배양 배지에서의 단백질의 생성
|
BR112012003077A2
(pt)
|
2009-08-14 |
2019-09-24 |
Genentech Inc |
mercadorias biologicas para monitorar resposta em paciente para antagonistas de vegf
|
AR077848A1
(es)
|
2009-08-15 |
2011-09-28 |
Genentech Inc |
Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado
|
RU2571929C2
(ru)
|
2009-09-01 |
2015-12-27 |
Дженентек, Инк. |
Улучшенная очистка белка посредством модифицированного элюирования белка а
|
US8642515B2
(en)
|
2009-09-04 |
2014-02-04 |
University Of Louisville Research Foundation, Inc. |
Genetic determinants of prostate cancer risk
|
RU2012114094A
(ru)
|
2009-09-11 |
2013-10-20 |
Дженентек, Инк. |
Способ идентификации пациента с увеличенной вероятностью ответа на противораковый агент
|
WO2011034605A2
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
KR101557545B1
(ko)
|
2009-09-17 |
2015-10-06 |
에프. 호프만-라 로슈 아게 |
암 환자에서 진단 용도를 위한 방법 및 조성물
|
WO2011041391A1
(en)
|
2009-09-29 |
2011-04-07 |
Fraunhofer Usa, Inc. |
Influenza hemagglutinin antibodies, compositions, and related methods
|
DK2488204T3
(en)
|
2009-10-16 |
2016-06-06 |
Oncomed Pharm Inc |
Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents
|
MY176035A
(en)
|
2009-10-21 |
2020-07-22 |
Genentech Inc |
Genetic polymorphisms in age-related macular degeneration
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
EP2509626B1
(en)
|
2009-12-11 |
2016-02-10 |
F.Hoffmann-La Roche Ag |
Anti-vegf-c antibodies and methods using same
|
US8765432B2
(en)
|
2009-12-18 |
2014-07-01 |
Oligasis, Llc |
Targeted drug phosphorylcholine polymer conjugates
|
SG181834A1
(en)
|
2009-12-21 |
2012-07-30 |
Genentech Inc |
Antibody formulation
|
MY161868A
(en)
|
2009-12-23 |
2017-05-15 |
Genentech Inc |
Anti-bv8 antibodies and uses thereof
|
EP2695889A1
(en)
|
2009-12-29 |
2014-02-12 |
Dr. Reddy's Laboratories Limited |
Protein purification by ion exchange
|
WO2011095596A1
(en)
|
2010-02-04 |
2011-08-11 |
Vivalis |
Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
|
UA114277C2
(uk)
|
2010-02-23 |
2017-05-25 |
Дженентек, Інк. |
Антиангіогенна терапія для лікування раку яєчника
|
KR101878369B1
(ko)
|
2010-03-22 |
2018-07-16 |
제넨테크, 인크. |
단백질-함유 제제의 안정화에 유용한 조성물 및 방법
|
TWI426920B
(zh)
|
2010-03-26 |
2014-02-21 |
Hoffmann La Roche |
雙專一性、雙價抗-vegf/抗-ang-2抗體
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
US10660965B2
(en)
|
2010-03-29 |
2020-05-26 |
Abraxis Bioscience, Llc |
Methods of enhancing drug delivery and effectiveness of therapeutic agents
|
SI2552415T1
(sl)
|
2010-03-29 |
2017-03-31 |
Abraxis Bioscience, Llc |
Metode za zdravljenje raka
|
WO2011133521A2
(en)
|
2010-04-19 |
2011-10-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
|
AR081361A1
(es)
|
2010-04-30 |
2012-08-29 |
Molecular Partners Ag |
Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
|
MX2012012743A
(es)
|
2010-05-03 |
2012-11-23 |
Genentech Inc |
Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
|
KR101551295B1
(ko)
|
2010-05-17 |
2015-09-08 |
이엠디 밀리포어 코포레이션 |
생체분자 정제용 자극 반응성 중합체
|
CA2800728C
(en)
|
2010-05-28 |
2020-10-27 |
Genentech, Inc. |
Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
SG186112A1
(en)
|
2010-06-04 |
2013-01-30 |
Abraxis Bioscience Llc |
Methods of treatment of pancreatic cancer
|
CN103068367B
(zh)
|
2010-06-24 |
2016-09-07 |
弗·哈夫曼-拉罗切有限公司 |
用于稳定含有蛋白质的制剂的含有烷基糖苷的组合物和方法
|
CN102958536A
(zh)
|
2010-07-02 |
2013-03-06 |
基因泰克公司 |
用抗-vegf疗法治疗血管化色素上皮脱离
|
RU2571226C2
(ru)
|
2010-07-09 |
2015-12-20 |
Дженентек, Инк. |
Антитела против нейропилина и способы их применения
|
RU2013104039A
(ru)
|
2010-07-19 |
2014-08-27 |
Ф. Хоффманн-Ля Рош Аг |
Способ идентификации пациента с повышенной вероятностью ответа на противораковую терапию
|
EP2824457A1
(en)
|
2010-07-19 |
2015-01-14 |
F. Hoffmann-La Roche AG |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
RU2013109275A
(ru)
|
2010-08-03 |
2014-09-10 |
Эббви Инк. |
Иммуноглобулины с двумя вариабельными доменами и их применение
|
WO2012021773A1
(en)
|
2010-08-13 |
2012-02-16 |
Genentech, Inc. |
Antibodies to il-1beta and il-18, for treatment of disease
|
TW201208703A
(en)
|
2010-08-17 |
2012-03-01 |
Roche Glycart Ag |
Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
|
BR112013001847A2
(pt)
|
2010-08-24 |
2016-05-31 |
Hoffmann La Roche |
anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica
|
KR20130139884A
(ko)
|
2010-08-26 |
2013-12-23 |
애브비 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
WO2012030512A1
(en)
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
KR20130124513A
(ko)
|
2010-11-15 |
2013-11-14 |
파이브 프라임 테라퓨틱스, 인크. |
가용성 fgfr1 융합 단백질의 상승된 투약량에 의한 암 치료
|
EP2655413B1
(en)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
WO2012095514A1
(en)
|
2011-01-14 |
2012-07-19 |
Vivalis |
Recombinant protein production system
|
CN103403025B
(zh)
|
2011-02-28 |
2016-10-12 |
弗·哈夫曼-拉罗切有限公司 |
单价抗原结合蛋白
|
BR112013019975A2
(pt)
|
2011-02-28 |
2017-08-01 |
Hoffmann La Roche |
proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
|
EP3138581B1
(en)
|
2011-03-17 |
2019-01-02 |
The University of Birmingham |
Re-directed immunotherapy
|
EP2691417B1
(en)
|
2011-03-29 |
2018-08-01 |
Roche Glycart AG |
Antibody fc variants
|
US9527925B2
(en)
|
2011-04-01 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to VEGF and ANG2
|
BR112013025353A8
(pt)
|
2011-04-01 |
2018-01-02 |
Genentech Inc |
combinação de a) um composto de fórmula ia, composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, método para tratamento de um distúrbio hiperproliferativo em um mamífero, uso de um composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, kit e produto
|
US9932386B2
(en)
|
2011-04-20 |
2018-04-03 |
Acceleron Pharma, Inc. |
Endoglin polypeptides and uses thereof
|
US20140178398A1
(en)
|
2011-05-03 |
2014-06-26 |
Genentech, Inc |
Vascular disruption agents and uses thereof
|
WO2012172054A1
(en)
|
2011-06-16 |
2012-12-20 |
Scil Proteins Gmbh |
Modified multimeric ubiquitin proteins binding vegf-a
|
JP2014522843A
(ja)
|
2011-06-30 |
2014-09-08 |
ジェネンテック, インコーポレイテッド |
抗c−met抗体製剤
|
WO2013009767A2
(en)
|
2011-07-12 |
2013-01-17 |
Epitomics, Inc. |
Facs-based method for obtaining an antibody sequence
|
EP2551348B1
(en)
|
2011-07-29 |
2014-09-24 |
Icon Genetics GmbH |
Production of galactosylated N-glycans in plants
|
WO2013025944A1
(en)
|
2011-08-17 |
2013-02-21 |
Genentech, Inc. |
Inhibition of angiogenesis in refractory tumors
|
KR102091293B1
(ko)
|
2011-09-23 |
2020-03-20 |
온코메드 파마슈티칼스, 인크. |
Vegf/dll4 결합제 및 그의 용도
|
WO2013050155A1
(en)
|
2011-10-04 |
2013-04-11 |
Icon Genetics Gmbh |
Nicotiana benthamiana plants deficient in fucosyltransferase activity
|
US20130095118A1
(en)
|
2011-10-11 |
2013-04-18 |
Vaccinex, Inc. |
Use of Semaphorin-4D Binding Molecules for Modulation of Blood Brain Barrier Permeability
|
BR112014008819A8
(pt)
|
2011-10-13 |
2017-09-12 |
Aerpio Therapeutics Inc |
Métodos para o tratamento de síndrome de vazamento vascular e câncer
|
JP2014532072A
(ja)
*
|
2011-10-13 |
2014-12-04 |
エアピオ セラピューティックス, インコーポレイテッド |
眼疾患の治療
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
EP2788026A4
(en)
|
2011-12-05 |
2015-08-05 |
Univ Duke |
V1V2 IMMUNOGENIC
|
US8790652B2
(en)
|
2011-12-06 |
2014-07-29 |
Vaccinex, Inc. |
Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
|
WO2013091903A1
(en)
|
2011-12-22 |
2013-06-27 |
Novo Nordisk A/S |
Anti-crac channel antibodies
|
SI2794635T1
(sl)
|
2011-12-22 |
2018-12-31 |
F. Hoffmann-La Roche Ag |
Ionskoizmenjevalna membranska kromatografija
|
TW201333035A
(zh)
|
2011-12-30 |
2013-08-16 |
Abbvie Inc |
針對il-13及/或il-17之雙特異性結合蛋白
|
EP2802346B1
(en)
|
2012-01-13 |
2018-09-12 |
F.Hoffmann-La Roche Ag |
Biological markers for identifying patients for treatment with vegf antagonists
|
WO2013119966A2
(en)
|
2012-02-10 |
2013-08-15 |
Genentech, Inc. |
Single-chain antibodies and other heteromultimers
|
US9475840B2
(en)
|
2012-02-27 |
2016-10-25 |
Universitat De Barcelona |
Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs
|
CA3056813A1
(en)
|
2012-03-13 |
2013-09-19 |
F. Hoffmann-La Roche Ag |
Combination therapy for the treatment of ovarian cancer
|
MY171729A
(en)
|
2012-03-27 |
2019-10-25 |
Genentech Inc |
Improved harvest operations for recombinant proteins
|
JP6335875B2
(ja)
|
2012-03-30 |
2018-05-30 |
ジェネンテック, インコーポレイテッド |
癌の治療のための診断法及び組成物
|
MX360110B
(es)
|
2012-04-20 |
2018-10-23 |
Merus Nv |
Metodos y medios para la produccion de moleculas de tipo ig.
|
WO2013170182A1
(en)
|
2012-05-11 |
2013-11-14 |
Synta Pharmaceuticals Corp. |
Treating cancer with an hsp90 inhibitory compound
|
US10494440B2
(en)
|
2012-05-11 |
2019-12-03 |
Vaccinex, Inc. |
Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
|
SG10201603055WA
(en)
|
2012-05-31 |
2016-05-30 |
Genentech Inc |
Methods Of Treating Cancer Using PD-L1 Axis Binding Antagonists And VEGF Antagonists
|
KR102386843B1
(ko)
|
2012-06-01 |
2022-04-15 |
노파르티스 아게 |
시린지
|
WO2013182668A1
(en)
|
2012-06-08 |
2013-12-12 |
F. Hoffmann-La Roche Ag |
Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
|
BR112014032193A2
(pt)
|
2012-06-27 |
2017-06-27 |
Hoffmann La Roche |
métodos de produção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação e uso de anticorpo biespecífico
|
CN104411718B
(zh)
|
2012-06-27 |
2018-04-24 |
弗·哈夫曼-拉罗切有限公司 |
用于制备包含特异性结合靶的至少一种结合实体的抗体Fc区缀合物的方法及其用途
|
JOP20200175A1
(ar)
|
2012-07-03 |
2017-06-16 |
Novartis Ag |
حقنة
|
EP3495387B1
(en)
|
2012-07-13 |
2021-09-01 |
Roche Glycart AG |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
SG11201500903XA
(en)
|
2012-08-07 |
2015-03-30 |
Genentech Inc |
Combination therapy for the treatment of glioblastoma
|
RU2681928C2
(ru)
|
2012-09-19 |
2019-03-13 |
Дженентек, Инк. |
Способы и композиции для предотвращения ошибки включения норлейцина в белки
|
US20140227252A1
(en)
|
2012-10-31 |
2014-08-14 |
Oncomed Pharmaceuticals , Inc. |
Methods and Monitoring of Treatment with a DLL4 Antagonist
|
RU2017137740A
(ru)
|
2012-11-01 |
2019-02-11 |
Эббви Инк. |
Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения
|
WO2014074218A1
(en)
|
2012-11-12 |
2014-05-15 |
Redwood Bioscience, Inc. |
Compounds and methods for producing a conjugate
|
EP2920148B1
(en)
|
2012-11-16 |
2019-06-12 |
The Regents of the University of California |
Pictet-spengler ligation for protein chemical modification
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
UY35195A
(es)
|
2012-12-18 |
2014-07-31 |
Novartis Ag |
Composiciones y metodos para proteinas de accion prolongada
|
WO2014100095A1
(en)
|
2012-12-19 |
2014-06-26 |
Genentech, Inc. |
Methods and compositions for radiohalogen protein labeling
|
AU2014205369B2
(en)
|
2013-01-11 |
2018-08-09 |
Massachusetts Eye And Ear Infirmary |
CYP450 lipid metabolites reduce inflammation and angiogenesis
|
WO2014118643A2
(en)
|
2013-02-04 |
2014-08-07 |
Vascular Biogenics Ltd. |
Methods of inducing responsiveness to anti-angiogenic agent
|
RU2699007C2
(ru)
|
2013-02-18 |
2019-09-02 |
Ведженикс Пти Лимитед |
Молекулы, связывающие лиганды, и их применение
|
MY185551A
(en)
|
2013-03-13 |
2021-05-19 |
Genentech Inc |
Antibody formulations
|
BR112015023797A2
(pt)
|
2013-03-15 |
2017-10-24 |
Abbvie Inc |
proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
|
US9441035B2
(en)
|
2013-03-15 |
2016-09-13 |
Genentech, Inc. |
Cell culture media and methods of antibody production
|
US9707154B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
CA2904806C
(en)
|
2013-04-29 |
2021-11-23 |
F. Hoffmann-La Roche Ag |
Human fcrn-binding modified antibodies and methods of use
|
MX2015015426A
(es)
|
2013-05-23 |
2016-06-10 |
Five Prime Therapeutics Inc |
Metodos de tratamiento de cancer.
|
KR101541478B1
(ko)
*
|
2013-05-31 |
2015-08-05 |
동아쏘시오홀딩스 주식회사 |
항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
|
JP6611709B2
(ja)
|
2013-06-25 |
2019-11-27 |
バクシネックス インコーポレーティッド |
腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−4d阻害分子の使用
|
CN110193009A
(zh)
|
2013-07-12 |
2019-09-03 |
伊维希比奥公司 |
用于治疗或预防眼科病的方法
|
KR20160042438A
(ko)
|
2013-08-12 |
2016-04-19 |
제넨테크, 인크. |
보체-연관 상태의 치료를 위한 조성물 및 방법
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
HUE052447T2
(hu)
|
2013-09-08 |
2021-04-28 |
Kodiak Sciences Inc |
A VIII. tényezõs zwitterionos polimer konjugációk
|
NZ630881A
(en)
|
2013-10-10 |
2016-03-31 |
Vaccinex Inc |
Use of semaphorin-4d binding molecules for treatment of atherosclerosis
|
BR112016006929A2
(pt)
|
2013-10-11 |
2017-09-19 |
Hoffmann La Roche |
Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
|
NZ630892A
(en)
|
2013-10-21 |
2016-03-31 |
Vaccinex Inc |
Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
|
CN105899225A
(zh)
|
2013-10-25 |
2016-08-24 |
阿塞勒隆制药公司 |
用于治疗纤维化疾病的内皮联蛋白肽
|
ES2875878T3
(es)
|
2013-11-18 |
2021-11-11 |
Formycon Ag |
Composición farmacéutica de un anticuerpo anti-VEGF
|
WO2015081282A1
(en)
|
2013-11-27 |
2015-06-04 |
Redwood Bioscience, Inc. |
Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
|
MX2015014724A
(es)
*
|
2013-12-31 |
2016-06-02 |
Dev Center Biotechnology |
Anticuerpos anti-factor de crecimiento endotelial vascular (vegf) y uso de los mismos.
|
MX2016008782A
(es)
|
2014-01-15 |
2016-09-08 |
Hoffmann La Roche |
Variantes de region fc con union mejorada de la proteina a.
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
US10100115B2
(en)
|
2014-02-14 |
2018-10-16 |
Macrogenics, Inc. |
Methods for the treatment of vascularizing cancers
|
WO2015124588A1
(en)
|
2014-02-18 |
2015-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway
|
EP3110941A4
(en)
|
2014-02-25 |
2017-10-18 |
Dr. Reddy's Laboratories Ltd. |
Process for modifying galactosylation and g0f content of a glycoprotein composition by glutamine supplementation
|
WO2015135884A1
(en)
|
2014-03-10 |
2015-09-17 |
Richter Gedeon Nyrt. |
Immunoglobulin purification using pre-cleaning steps
|
HUE048531T2
(hu)
|
2014-03-14 |
2020-07-28 |
Novartis Ag |
Antitest molekulák a LAG-3-hoz és ezek felhasználása
|
RU2016141385A
(ru)
|
2014-03-24 |
2018-04-28 |
Дженентек, Инк. |
Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
|
JP6588461B2
(ja)
|
2014-03-31 |
2019-10-09 |
ジェネンテック, インコーポレイテッド |
抗血管新生剤及びox40結合アゴニストを含む併用療法
|
PE20161440A1
(es)
|
2014-05-01 |
2017-01-26 |
Genentech Inc |
Variantes del anticuerpo anti-factor d y sus usos
|
EP3492495A1
(en)
|
2014-05-12 |
2019-06-05 |
Formycon AG |
Pre-filled plastic syringe containing a vegf antagonist
|
EP3760229A3
(en)
|
2014-05-15 |
2021-04-07 |
Bristol-Myers Squibb Company |
Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
JP6668260B2
(ja)
|
2014-06-06 |
2020-03-18 |
レッドウッド バイオサイエンス, インコーポレイテッド |
抗her2抗体−メイタンシンコンジュゲート及びその方法
|
US20170290876A1
(en)
|
2014-06-25 |
2017-10-12 |
Novartis Ag |
Compositions and methods for long acting proteins
|
EP3160991A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Compositions and methods for long acting proteins
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
SG11201700097WA
(en)
|
2014-07-09 |
2017-02-27 |
Genentech Inc |
Ph adjustment to improve thaw recovery of cell banks
|
CN106460067A
(zh)
|
2014-07-14 |
2017-02-22 |
豪夫迈·罗氏有限公司 |
诊断方法和用于治疗成胶质细胞瘤的组合物
|
CA2957717C
(en)
|
2014-08-12 |
2021-10-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
|
WO2016025647A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
|
CN105330739B
(zh)
*
|
2014-08-12 |
2020-12-25 |
中美华世通生物医药科技(武汉)有限公司 |
与人血管内皮生长因子特异性结合的抗体或其抗原结合片段及其用途
|
US9993551B2
(en)
|
2014-09-13 |
2018-06-12 |
Novartis Ag |
Combination therapies of EGFR inhibitors
|
ES2949173T3
(es)
|
2014-09-15 |
2023-09-26 |
Hoffmann La Roche |
Formulaciones de anticuerpo
|
ES2774448T3
(es)
|
2014-10-03 |
2020-07-21 |
Novartis Ag |
Terapias de combinación
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
TN2017000129A1
(en)
|
2014-10-14 |
2018-10-19 |
Dana Farber Cancer Inst Inc |
Antibody molecules to pd-l1 and uses thereof
|
CN107208076A
(zh)
|
2014-10-17 |
2017-09-26 |
科达制药 |
丁酰胆碱酯酶两性离子聚合物缀合物
|
EP3209769B1
(en)
|
2014-10-24 |
2020-08-05 |
The Board of Trustees of the Leland Stanford Junior University |
Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
|
CN107530419B
(zh)
|
2014-10-31 |
2021-05-18 |
昂考梅德药品有限公司 |
治疗疾病的组合疗法
|
CA2960297A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
CN107001482B
(zh)
|
2014-12-03 |
2021-06-15 |
豪夫迈·罗氏有限公司 |
多特异性抗体
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
ES2907148T3
(es)
|
2014-12-11 |
2022-04-22 |
Bayer Healthcare Llc |
Tratamiento de la degeneración macular asociada a la edad con una pequeña lesión de neovascularización coroidea activa
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
WO2016106340A2
(en)
|
2014-12-23 |
2016-06-30 |
Genentech, Inc. |
Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
|
WO2016120753A1
(en)
*
|
2015-01-28 |
2016-08-04 |
Pfizer Inc. |
Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
|
KR20220070057A
(ko)
|
2015-03-09 |
2022-05-27 |
인테크린 테라퓨틱스, 아이엔씨. |
비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
|
EP3286315B1
(en)
|
2015-04-24 |
2021-05-26 |
F. Hoffmann-La Roche AG |
Methods of identifying bacteria comprising binding polypeptides
|
US20180155429A1
(en)
|
2015-05-28 |
2018-06-07 |
Bristol-Myers Squibb Company |
Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
|
US11078278B2
(en)
|
2015-05-29 |
2021-08-03 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
CA2988420A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
JP2018522887A
(ja)
|
2015-07-14 |
2018-08-16 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
免疫チェックポイント阻害剤を使用する癌の処置法
|
US10266589B2
(en)
|
2015-07-29 |
2019-04-23 |
Allergan, Inc. |
Heavy chain only antibodies to ANG-2
|
US20180340025A1
(en)
|
2015-07-29 |
2018-11-29 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
JP6878405B2
(ja)
|
2015-07-29 |
2021-05-26 |
ノバルティス アーゲー |
Pd−1に対する抗体分子を含む組み合わせ治療
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
HU231463B1
(hu)
|
2015-08-04 |
2024-01-28 |
Richter Gedeon Nyrt. |
Módszer rekombináns proteinek galaktóz tartalmának növelésére
|
US10308711B2
(en)
|
2015-08-14 |
2019-06-04 |
Allergan, Inc. |
Heavy chain only antibodies to PDGF
|
EP3337508A4
(en)
*
|
2015-08-21 |
2019-04-03 |
Immunomedics, Inc. |
MONOCLONAL ANTI-HLA-DR ANTIBODY FOR SUBCUTANEOUS ADMINISTRATION FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANT TUMORS
|
CA2994888A1
(en)
|
2015-09-17 |
2017-03-23 |
Immunogen, Inc. |
Therapeutic combinations comprising anti-folr1 immunoconjugates
|
WO2017046140A1
(en)
|
2015-09-18 |
2017-03-23 |
Bayer Pharma Aktiengesellschaft |
Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
|
DK3353196T3
(da)
|
2015-09-22 |
2023-02-20 |
Inst Nat Sante Rech Med |
Polypeptider, der er i stand til at inhibere bindingen mellem leptin og neuropilin-1
|
KR20180053315A
(ko)
|
2015-09-23 |
2018-05-21 |
제넨테크, 인크. |
항-vegf 항체의 최적화된 변이체들
|
CN109071644B
(zh)
|
2015-09-23 |
2023-09-19 |
昂考梅德药品有限公司 |
治疗癌症的方法和组合物
|
WO2017055325A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of nk cells in a tissue sample
|
WO2017055319A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of b cells in a tissue sample
|
WO2017055327A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of endothelial cells in a tissue sample
|
WO2017055322A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of neutrophils in a tissue sample
|
WO2017055320A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
|
WO2017055321A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of fibroblasts in a tissue sample
|
WO2017055326A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
WO2017055324A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cells of monocytic origin in a tissue sample
|
EP3362095B1
(en)
|
2015-10-13 |
2020-11-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
|
EP3368565A1
(en)
|
2015-10-30 |
2018-09-05 |
H. Hoffnabb-La Roche Ag |
Anti-factor d antibody formulations
|
CN108289951A
(zh)
|
2015-10-30 |
2018-07-17 |
豪夫迈·罗氏有限公司 |
抗-因子d抗体和缀合物
|
CN108472382A
(zh)
|
2015-10-30 |
2018-08-31 |
豪夫迈·罗氏有限公司 |
抗-因子d抗体变体缀合物及其用途
|
ES2870141T3
(es)
|
2015-10-30 |
2021-10-26 |
Hoffmann La Roche |
Anticuerpos anti-HtrA1 y procedimientos de uso de los mismos
|
WO2017079112A1
(en)
|
2015-11-03 |
2017-05-11 |
Janssen Biotech, Inc. |
Antibodies specifically binding pd-1 and their uses
|
US20190209697A1
(en)
|
2015-11-05 |
2019-07-11 |
The Regents Of The University Of California |
Cells labelled with lipid conjugates and methods of use thereof
|
WO2017087798A1
(en)
|
2015-11-18 |
2017-05-26 |
Formycon Ag |
Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
|
WO2017087871A1
(en)
|
2015-11-18 |
2017-05-26 |
Sio2 Medical Products, Inc. |
Pharmaceutical package for ophthalmic formulations
|
CA3005692A1
(en)
|
2015-11-18 |
2017-05-26 |
Formycon Ag |
Pre-filled plastic syringe containing a vegf antagonist
|
AU2016364817B2
(en)
|
2015-12-03 |
2020-05-07 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Pd−1に対する抗体分子およびその使用
|
RU2744860C2
(ru)
|
2015-12-30 |
2021-03-16 |
Кодиак Сайенсиз Инк. |
Антитела и их конъюгаты
|
JP6953433B2
(ja)
|
2016-01-26 |
2021-10-27 |
フォーマイコン アーゲーFormycon Ag |
Vegfアンタゴニストを含む液体医薬組成物および同医薬組成物を含有する充填済みシリンジ
|
US10894823B2
(en)
|
2016-03-24 |
2021-01-19 |
Gensun Biopharma Inc. |
Trispecific inhibitors for cancer treatment
|
CA3019373A1
(en)
|
2016-03-29 |
2017-10-05 |
Geltor, Inc. |
Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
|
EP3443120A2
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
CA3019921A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
BR112018073781A2
(pt)
|
2016-05-20 |
2019-02-26 |
Biohaven Pharmaceutical Holding Company Ltd. |
uso de agentes de modulação de glutamato com imunoterapias para o tratamento de câncer
|
CN109890982B
(zh)
|
2016-07-08 |
2023-07-07 |
基因泰克公司 |
通过nrf2及其下游目标基因的表达状态和突变状态诊断和治疗癌症的方法
|
EP3482205A1
(en)
|
2016-07-08 |
2019-05-15 |
H. Hoffnabb-La Roche Ag |
Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
|
WO2018011166A2
(en)
|
2016-07-12 |
2018-01-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
MX2019000727A
(es)
|
2016-07-20 |
2019-05-02 |
Aerpio Therapeutics Inc |
Anticuerpos monoclonales humanizados que tienen como blanco ve-ptp (hptp-b).
|
WO2018018613A1
(zh)
|
2016-07-29 |
2018-02-01 |
广东东阳光药业有限公司 |
一种提高抗体纯度的细胞培养基和培养方法
|
CN106222129A
(zh)
*
|
2016-07-29 |
2016-12-14 |
广东东阳光药业有限公司 |
一种提高抗体纯度的细胞培养基和培养方法
|
MX2019001635A
(es)
|
2016-08-12 |
2019-06-10 |
Genentech Inc |
Terapia de combinacion con un inhibidor de mek, un inhibidor del eje de pd-1, y un inhibidor de vegf.
|
WO2018037001A1
(en)
*
|
2016-08-23 |
2018-03-01 |
Medimmune Limited |
Anti-vegf-a antibodies and uses thereof
|
US20190300607A1
(en)
|
2016-10-12 |
2019-10-03 |
Daiichi Sankyo Company, Limited |
Composition containing anti-robo4 antibody and other agents
|
US11192925B2
(en)
|
2016-10-19 |
2021-12-07 |
Adverum Biotechnologies, Inc. |
Modified AAV capsids and uses thereof
|
US10537637B2
(en)
|
2017-01-05 |
2020-01-21 |
Gensun Biopharma Inc. |
Checkpoint regulator antagonists
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
JP2020505438A
(ja)
|
2017-01-10 |
2020-02-20 |
ノダス・セラピューティクスNodus Therapeutics |
インテグリン結合性ポリペプチド−Fc融合タンパク質および免疫調節物質を用いる併用がん治療法
|
WO2018160841A1
(en)
|
2017-03-01 |
2018-09-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
EP3601332A1
(en)
*
|
2017-03-24 |
2020-02-05 |
Council of Scientific and Industrial Research |
A process for the purification of recombinant antibody fragments
|
AU2018249822A1
(en)
|
2017-04-03 |
2019-10-31 |
Coherus Biosciences Inc. |
PPArgamma agonist for treatment of progressive supranuclear palsy
|
JOP20190245A1
(ar)
|
2017-04-20 |
2019-10-15 |
Novartis Ag |
أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
|
MX2019013750A
(es)
|
2017-05-19 |
2020-07-20 |
Council Scient Ind Res |
Un metodo para producir ranibizumab humanizado recombinante replegado.
|
WO2018217995A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
CA3063995A1
(en)
|
2017-05-24 |
2018-11-29 |
Sio2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
CU24606B1
(es)
|
2017-06-22 |
2022-06-06 |
Novartis Ag |
Moléculas de anticuerpo que se unen a cd73
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
US11931327B2
(en)
|
2017-07-04 |
2024-03-19 |
Daiichi Sankyo Company, Limited |
Drug for retinal degenerative disease associated with photoreceptor degeneration
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
WO2019057946A1
(en)
|
2017-09-25 |
2019-03-28 |
F. Hoffmann-La Roche Ag |
MULTI-CYCLIC AROMATIC COMPOUNDS AS D-FACTOR INHIBITORS
|
US11180541B2
(en)
|
2017-09-28 |
2021-11-23 |
Geltor, Inc. |
Recombinant collagen and elastin molecules and uses thereof
|
US20210322574A1
(en)
|
2017-10-20 |
2021-10-21 |
Vascular Biogenics Ltd. |
Diagnostic methods for anti-angiogenic agent therapy
|
BR112020012336A2
(pt)
|
2017-12-19 |
2021-03-30 |
Akouos, Inc. |
Administração de anticorpos terapêuticos mediada por aav para o ouvido interno
|
EP3731864A1
(en)
|
2017-12-29 |
2020-11-04 |
F. Hoffmann-La Roche SA |
Anti-vegf antibodies and methods of use
|
CN110003328B
(zh)
*
|
2018-01-05 |
2022-04-19 |
百奥泰生物制药股份有限公司 |
一种长效低毒的重组抗vegf人源化单克隆抗体及其生产方法
|
IL276383B2
(en)
|
2018-02-06 |
2024-01-01 |
Hoffmann La Roche |
Treatment of ophthalmological diseases
|
TWI823906B
(zh)
|
2018-03-09 |
2023-12-01 |
美商艾吉納斯公司 |
抗-cd73 抗體及其使用方法
|
AU2019254237A1
(en)
|
2018-04-16 |
2020-12-03 |
Onquality Pharmaceuticals China Ltd. |
Method for preventing or treating side effects of cancer therapy
|
CN116585466A
(zh)
|
2018-05-10 |
2023-08-15 |
瑞泽恩制药公司 |
含有高浓度vegf受体融合蛋白的制剂
|
JOP20200303A1
(ar)
|
2018-05-24 |
2020-11-23 |
Janssen Biotech Inc |
عوامل ربط psma واستخداماتها
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
WO2019229116A1
(en)
|
2018-05-31 |
2019-12-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Intravitreal delivery of a decorin polypeptide for the treatment of choroidal neovascularisation
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
WO2020006509A1
(en)
|
2018-06-29 |
2020-01-02 |
Gensun Biopharma, Inc. |
Antitumor antagonists
|
SG11202012582QA
(en)
|
2018-07-03 |
2021-01-28 |
Bristol Myers Squibb Co |
Methods of producing recombinant proteins
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
CN109053895B
(zh)
|
2018-08-30 |
2020-06-09 |
中山康方生物医药有限公司 |
抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
|
JP2022502367A
(ja)
|
2018-09-24 |
2022-01-11 |
エアーピオ ファーマシューティカルズ, インコーポレイテッド |
HPTP−β(VE−PTP)およびVEGFを標的にする多特異性抗体
|
MA53859A
(fr)
|
2018-10-10 |
2022-01-19 |
Boehringer Ingelheim Int |
Procédé de transfert de gaz de membrane dans une culture de bioréacteur à haute densité
|
CA3116324A1
(en)
|
2018-10-18 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
HUP1800376A2
(hu)
|
2018-11-07 |
2020-05-28 |
Richter Gedeon Nyrt |
Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer
|
WO2020109343A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Combination therapy for treatment of macular degeneration
|
CN109134651B
(zh)
*
|
2018-12-03 |
2019-02-22 |
上海复宏汉霖生物技术股份有限公司 |
一种抗vegf的单克隆抗体及其制备方法和应用
|
US20200207812A1
(en)
|
2018-12-07 |
2020-07-02 |
Coherus Biosciences, Inc. |
Methods for producing recombinant proteins
|
CN113226472A
(zh)
|
2018-12-17 |
2021-08-06 |
雷维托普有限公司 |
双免疫细胞衔接物
|
MX2021011084A
(es)
|
2019-03-13 |
2021-10-22 |
Vascular Biogenics Ltd |
Metodos de terapia antitumoral.
|
SG11202110043TA
(en)
|
2019-04-01 |
2021-10-28 |
Genentech Inc |
Compositions and methods for stabilizing protein-containing formulations
|
HU231498B1
(hu)
|
2019-04-04 |
2024-05-28 |
Richter Gedeon Nyrt |
Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelõzõ flokkulálás alkalmazásával
|
EP3953380A4
(en)
|
2019-04-12 |
2023-01-25 |
Geltor, Inc. |
RECOMBINATION ELASTIN AND ASSOCIATED PRODUCTION
|
MA55717A
(fr)
|
2019-04-19 |
2022-02-23 |
Janssen Biotech Inc |
Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
|
TW202106699A
(zh)
|
2019-04-26 |
2021-02-16 |
美商愛德維仁生物科技公司 |
用於玻璃體內遞送之變異體aav蛋白殼
|
CN114269376A
(zh)
|
2019-05-03 |
2022-04-01 |
豪夫迈·罗氏有限公司 |
用抗pd-l1抗体治疗癌症的方法
|
EP3965816A1
(en)
|
2019-05-06 |
2022-03-16 |
MedImmune Limited |
Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer
|
WO2020263312A1
(en)
|
2019-06-28 |
2020-12-30 |
Gensun Biopharma, Inc. |
ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
|
KR20220039777A
(ko)
|
2019-08-01 |
2022-03-29 |
브리스톨-마이어스 스큅 컴퍼니 |
유가식 세포 배양에서 단백질 생산성을 개선시키는 방법
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
EP4041312A4
(en)
|
2019-10-10 |
2023-12-20 |
Kodiak Sciences Inc. |
METHOD FOR TREATING AN EYE DISORDER
|
WO2021072210A1
(en)
|
2019-10-11 |
2021-04-15 |
Coherus Biosciences, Inc. |
Methods of purifying ranibizumab or a ranibizumab variant
|
WO2021072182A1
(en)
|
2019-10-11 |
2021-04-15 |
Coherus Biosciences, Inc. |
Methods for producing ranibizumab
|
WO2021100034A1
(en)
|
2019-11-19 |
2021-05-27 |
Protalix Ltd. |
Removal of constructs from transformed cells
|
IL293241A
(en)
|
2019-11-25 |
2022-07-01 |
Akeso Biopharma Inc |
Bispecific antibody, anti-1-pd, anti-vegfa, pharmaceutical preparation containing it and its use
|
US20230151425A1
(en)
|
2020-03-11 |
2023-05-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
|
US11760797B2
(en)
|
2020-03-13 |
2023-09-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
JP2023520515A
(ja)
|
2020-04-03 |
2023-05-17 |
ジェネンテック, インコーポレイテッド |
がんに対する治療方法及び診断方法
|
CN116133679A
(zh)
|
2020-06-30 |
2023-05-16 |
门德斯有限公司 |
白血病衍生细胞在卵巢癌疫苗中的用途
|
PE20231093A1
(es)
|
2020-07-16 |
2023-07-18 |
Novartis Ag |
Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas
|
US20230357815A1
(en)
|
2020-09-22 |
2023-11-09 |
Bristol-Myers Squibb Company |
Methods for increasing productivity of therapeutic proteins
|
US20230374447A1
(en)
|
2020-10-05 |
2023-11-23 |
Protalix Ltd. |
Dicer-like knock-out plant cells
|
IL302089A
(en)
|
2020-10-15 |
2023-06-01 |
Hoffmann La Roche |
Non-covalent protein-hyaluronan conjugates for long-term ocular delivery
|
MX2023005529A
(es)
|
2020-11-13 |
2023-05-25 |
Genentech Inc |
Metodos y composiciones que comprenden un inhibidor de krasg12c y un inhibidor de vegf para tratar tumores solidos.
|
EP4255570A1
(en)
|
2020-12-01 |
2023-10-11 |
Akouos, Inc. |
Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
|
EP4281102A1
(en)
|
2021-01-22 |
2023-11-29 |
Mendus B.V. |
Methods of tumor vaccination
|
WO2022162518A2
(en)
|
2021-01-28 |
2022-08-04 |
Janssen Biotech, Inc. |
Psma binding proteins and uses thereof
|
CA3193662A1
(en)
|
2021-03-12 |
2022-09-15 |
Akeso Biopharma, Inc. |
Pharmaceutical combination containing anti-pd-1-anti-vegfa bispecific antibody, and use thereof
|
CA3212351A1
(en)
|
2021-03-12 |
2022-09-15 |
Mendus B.V. |
Methods of vaccination and use of cd47 blockade
|
JP2024516230A
(ja)
|
2021-04-30 |
2024-04-12 |
ジェネンテック, インコーポレイテッド |
がんのための治療及び診断方法並びに組成物
|
WO2022247917A1
(zh)
|
2021-05-28 |
2022-12-01 |
上海瑞宏迪医药有限公司 |
衣壳变异的重组腺相关病毒及其应用
|
US20220389120A1
(en)
|
2021-06-03 |
2022-12-08 |
Gensun Biopharma Inc. |
Multispecific antagonists
|
AU2022302170A1
(en)
|
2021-07-02 |
2023-12-21 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating cancer
|
KR20240038008A
(ko)
|
2021-07-28 |
2024-03-22 |
에프. 호프만-라 로슈 아게 |
암 치료 방법 및 조성물
|
WO2023015234A1
(en)
|
2021-08-05 |
2023-02-09 |
Bristol-Myers Squibb Company |
Cell culture methods for producing therapeutic proteins
|
WO2023016516A1
(zh)
|
2021-08-13 |
2023-02-16 |
信达生物制药(苏州)有限公司 |
抗vegf a和vegf c双特异性抗体及其用途
|
EP4145456A1
(en)
|
2021-09-06 |
2023-03-08 |
Bayer AG |
Prediction of a change related to a macular fluid
|
WO2023049687A1
(en)
|
2021-09-21 |
2023-03-30 |
Bristol-Myers Squibb Company |
Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
|
WO2023080900A1
(en)
|
2021-11-05 |
2023-05-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating kidney cancer
|
AR128422A1
(es)
|
2022-02-02 |
2024-05-08 |
Akouos Inc |
Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular
|
WO2024040175A1
(en)
|
2022-08-18 |
2024-02-22 |
Pulmatrix Operating Company, Inc. |
Methods for treating cancer using inhaled angiogenesis inhibitor
|
CN117679505A
(zh)
|
2022-09-09 |
2024-03-12 |
中山康方生物医药有限公司 |
药物组合及用途
|